Comparison of Volume Retention and Biocompatibility of Acellular Dermal Matrix/Hyaluronic Acid Filler to Autologous Fat Grafts in a Mouse Model

Kim, Ji Hun; Kim, Sun Eung; Kim, Yu Jin; Kim, Yang Woo; Cheon, Young Woo

doi:10.1007/s00266-020-01680-8

Cited by 7 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 HA/MADM can also promote adipocyte survival via increased vascular endothelial growth factor expression 14 and showed higher volume retention than the fat graft in a mouse model. 16 Considering the pathogenesis of HIV-associated FLA, including reduced adipogenesis and increased adipocyte apoptosis, 5 HA/MADM may have an advantage over other filler materials by recovering the patient’s own adipose tissue. Limitations of our study include the relatively small sample size, absence of a control group, and lack of female patients.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Human Immunodeficiency Virus-Associated Facial Lipoatrophy With Hyaluronic Acid Filler Mixed With Micronized Cross-Linked Acellular Dermal Matrix

et al. 2022

View full text Add to dashboard Cite

Background Human immunodeficiency virus (HIV)-associated facial lipoatrophy (FLA) is a stigmatizing side effect associated with the use of highly active antiretroviral therapy. We sought to evaluate the safety and efficacy of the hyaluronic acid filler mixed with micronized cross-linked acellular dermal matrix (HA/MADM) in HIV-associated FLA. Methods We conducted an open-label safety and efficacy study in patients with HIV-associated FLA. Fourteen patients received single injection of the HA/MADM, and 13 patients completed the 24-week follow-up evaluation. Treatment efficacy, safety, and patient and physician satisfaction were evaluated. Repeated measure analysis of variance with post-hoc analysis with the Wilcoxon signed rank test was performed to compare and incorporate parameters at each time point. Results All 13 patients maintained a significant improvement of the Carruthers Lipoatrophy Severity Scale grade throughout the study period, along with improvement of the depressed volume due to lipoatrophy measured using a three-dimensional camera system. More than 80% of patients and physicians were satisfied with the treatment, and no treatment-related adverse events were reported, except for one case of transient subcutaneous nodule formation. Conclusion Our study findings suggest that injectable HA/MADM is a potentially effective and safe treatment option for treating HIV-positive patients with FLA.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Human Immunodeficiency Virus-Associated Facial Lipoatrophy With Hyaluronic Acid Filler Mixed With Micronized Cross-Linked Acellular Dermal Matrix

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We read with great interest the article entitled ''Comparison of Volume Retention and Biocompatibility of Acellular Dermal Matrix/Hyaluronic Acid Filler to Autologous Fat Grafts in a Mouse Model'' by Kim et al [1] in Aesthetic Plastic Surgery. In this article, the authors compared the volume retention and biocompatibility of acellular dermal matrix/hyaluronic acid filler (ADM/HA) with fat grafts.…”

Section: Sirmentioning

confidence: 99%